OmniAb (OABI) Total Non-Current Liabilities (2021 - 2026)
OmniAb (OABI) reported Total Non-Current Liabilities of $30.9 million for Q1 2026, down 5.06% year-over-year from $32.6 million in Q1 2025, and down 8.52% on a QoQ basis from $33.8 million in Q4 2025.
OmniAb (OABI) has 6 years of Total Non-Current Liabilities data on file, last reported at $30.9 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 5.06% year-over-year to $30.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.9 million (down 5.06% YoY) and the FY2025 annual result came in at $33.8 million, down 10.69% from the prior year.
- Total Non-Current Liabilities retreated to $30.9 million in Q1 2026 per OABI's latest filing, from $33.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $79.8 million in Q4 2022 and bottomed at $30.9 million in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $40.8 million (2024), against an average of $48.2 million.
- The widest annual swing landed in 2022, when Total Non-Current Liabilities gained 22.13%; it then slumped 38.44% in 2024.
- Tracing OABI's Total Non-Current Liabilities over 5 years: stood at $79.8 million in 2022, then slipped by 28.02% to $57.4 million in 2023, then tumbled by 34.09% to $37.9 million in 2024, then decreased by 10.69% to $33.8 million in 2025, then declined by 8.52% to $30.9 million in 2026.
- Per Business Quant, the three latest OABI Total Non-Current Liabilities figures stand at $30.9 million (Q1 2026), $33.8 million (Q4 2025), and $31.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 30.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.93 Mn |
| Dec 31, 2025 | 33.81 Mn |
| Sep 30, 2025 | 31.73 Mn |
| Jun 30, 2025 | 33.53 Mn |
| Mar 31, 2025 | 32.58 Mn |
| Dec 31, 2024 | 37.85 Mn |
| Sep 30, 2024 | 39.77 Mn |
| Jun 30, 2024 | 41.89 Mn |
| Mar 31, 2024 | 51.13 Mn |
| Dec 31, 2023 | 57.44 Mn |
| Sep 30, 2023 | 63.64 Mn |
| Jun 30, 2023 | 68.05 Mn |
| Mar 31, 2023 | 72.20 Mn |
| Dec 31, 2022 | 79.79 Mn |
| Dec 31, 2021 | 65.33 Mn |